within Pharmacolibrary.Drugs.ATC.N;

model N07AA51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.00022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Neostigmine is a reversible acetylcholinesterase inhibitor used to enhance neuromuscular transmission. It is commonly used in the treatment of myasthenia gravis, reversal of non-depolarizing neuromuscular blockade post-surgery, and sometimes in the management of postoperative ileus and urinary retention. In combination products (ATC: N07AA51), it is typically combined with other cholinesterase inhibitors or anticholinergic agents. Neostigmine and its combinations are still approved for use today in many countries.</p><h4>Pharmacokinetics</h4><p>General adult population, both sexes, no specific disease or condition distinction, pharmacokinetic parameters derived primarily from pharmacokinetic studies in healthy volunteers with combination formulations.</p><h4>References</h4><ol><li><p>Morris, RB, et al., &amp; Fahey, MR (1981). Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. <i>Anesthesiology</i> 54(5) 399–401. DOI:<a href=&quot;https://doi.org/10.1097/00000542-198105000-00009&quot;>10.1097/00000542-198105000-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7224209/&quot;>https://pubmed.ncbi.nlm.nih.gov/7224209</a></p></li><li><p>Pihlajamäki, K, et al., &amp; Jaakkola, P (1986). Pharmacokinetics of atropine in children. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 24(5) 236–239. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3733273/&quot;>https://pubmed.ncbi.nlm.nih.gov/3733273</a></p></li><li><p>de Kam, PJ, et al., &amp; Peeters, PA (2013). Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia. <i>Clinical drug investigation</i> 33(8) 545–551. DOI:<a href=&quot;https://doi.org/10.1007/s40261-013-0095-8&quot;>10.1007/s40261-013-0095-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23824662/&quot;>https://pubmed.ncbi.nlm.nih.gov/23824662</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07AA51;
